Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.

摘要: Infection with coronavirus SARS-CoV-2, causing COVID-19 disease, leads to inflammation and a prothrombotic state. This rapid systematic review aims synthesize evidence on thromboembolism incidence outcomes antithrombotic therapies in COVID-19. We searched MEDLINE (Ovid), Cochrane Rapid Reviews, PROSPERO, the WHO Database from January 1, 2003, April 22, 2020, for studies meeting pre-specified inclusion criteria. One investigator identified articles inclusion, abstracted data, performed quality assessment, second reviewer checking. Incidence of among hospitalized patients ranged 25 53% 4 retrospective series. 3 (1 cohort study, 1 prospective uncontrolled observational case series) examining who received therapies. These all included different interventions (thromboprophylaxis unfractionated heparin (UFH) or low molecular-weight (LMWH); an intensive thromboprophylaxis protocol LMWH, antithrombin, clopidogrel; salvage therapy tissue plasminogen activator heparin). are overall poor due methodological limitations including unclear patient selection protocols, lack reporting adjustment baseline characteristics, inadequate duration follow-up, partial outcomes. New does not warrant change current guidance patients. Prospective trials treatment strategies urgently needed.